Effect of pentoxifylline on restless leg syndrome

The effect of pentoxifylline on reducing incidence of restless leg syndrome in patients undergoing hemodialysis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180219038797N1

Enrollment

Registered

2018-04-20

Start date

2018-03-06

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Restless Leg Syndrome. Restless legs syndrome

Interventions

Intervention 1: Intervention group: prescription of 1 pentoxifylline tablet (400 mg) daily for 3 months. Intervention 2: Control group: prescription of 1 placebo daily for 3 months.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the patients undergoing hemodialysis that have Informed consent

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Death

Design outcomes

Primary

Measure	Time frame
Pain and comfort of legs. Timepoint: At the end of each month for 3 months. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Saberi Rad

Sabzevar University of Medical Sciences

rsaberirad@medsab.ac.ir+98 51 4464 7777

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026